Vertex Pharmaceuticals IncChange company Symbol lookupSelect an option...VRTX Vertex Pharmaceuticals IncHBI HanesBrands IncTMKR Tastemaker Acquisition CorpSPY SPDR® S&P 500 ETF TrustSTOR STORE Capital CorpPIPP^ Pine Island Acquisition CorpPEP PepsiCo Inc$NASI5000LMN NASDAQ Asia Cnsmr Svcs Large Mid CapPNM PNM Resources IncCBLAQ CBL & Associates Properties IncGo
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
|
|
|
|
| |
Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.
Valuation Ratios
- Price/Earnings (TTM)
- 20.57x
- Price/Sales (TTM)
- 8.88x
- Price/Book (MRQ)
- 6.34x
- Price/Cash Flow (TTM)
- 19.53x
MRQ = Most Recent Quarter
Price Performance
Financial Statements
Balance sheet
Values displayed are in millions.
Income statement
Values displayed are in millions.
Cash flow
Values displayed are in millions.
Company Officers
- Jeffrey M. LeidenChmn.
- Reshma KewalramaniPres.
- Charles F. WagnerCFO
- Michael J. PariniExec.VP
- David AltshulerExec.VP
Address
- 50 Northern Ave
- Boston, MA 02210-1862
- Phone: (617) 341-6393
- https://www.vrtx.com/
Insider Trading
During the most recent quarter, 15K shares were bought, and 95K shares were sold in insider trading.
Insider trading information report provided by Copyright © 2021. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.